Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026

INOVIO PHARMACEUTICALS, INC.

Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).
Cash, equivalents & short-term investments $58.5M as of Dec 31, 2025; estimated runway into Q4 2026 with Q1 2026 burn ~$22M.
FDA accepted BLA for INO-3107 under accelerated approval program; PDUFA date Oct 30, 2026; FDA questioned accelerated eligibility.
Published INO-3107 Phase 1/2 and long-term data in Nature Communications and The Laryngoscope showing reduced surgeries.
Entered clinical trial collaboration with Akeso to evaluate INO-5412 + cadonilimab for glioblastoma in Dana-Farber INSIGhT trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

INOVIO PHARMACEUTICALS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 12, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001055726-26-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.